Patrick S Ward,
Jay Patel,
David R Wise,
Omar Abdel-Wahab,
Bryson D Bennett,
Hilary A Coller,
Justin R Cross,
Valeria R Fantin, Cyrus V Hedvat,
Alexander E Perl,
Joshua D Rabinowitz,
Martin Carroll,
Shinsan M Su,
Kim A Sharp,
Ross L Levine,
Craig B Thompson
[show abstract]
[hide abstract]
ABSTRACT: The somatic mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) observed in gliomas can lead to the production of 2-hydroxyglutarate (2HG). Here, we report that tumor 2HG is elevated in a high percentage of patients with cytogenetically normal acute myeloid leukemia (AML). Surprisingly, less than half of cases with elevated 2HG possessed IDH1 mutations. The remaining cases with elevated 2HG had mutations in IDH2, the mitochondrial homolog of IDH1. These data demonstrate that a shared feature of all cancer-associated IDH mutations is production of the oncometabolite 2HG. Furthermore, AML patients with IDH mutations display a significantly reduced number of other well characterized AML-associated mutations and/or associated chromosomal abnormalities, potentially implicating IDH mutation in a distinct mechanism of AML pathogenesis.
Cancer cell 02/2010; 17(3):225-34. · 25.29 Impact Factor
